Navigation Links
Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
Date:11/2/2009

FREMONT, Calif., Nov. 2 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will present a case history of QPI-1002, the first systemically administered synthetic siRNA, at the Joint Symposium of the 5th Annual Meeting of Oligonucleotide Therapeutics Society and the 19th Antisense Symposium in Fukuoka, Japan, November 3-6, 2009. The company also announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, will participate in the RNAi for Developing Targeted Therapeutics track at this year's CHI Discovery on Target Conference in Boston, November 2-4, 2009.

Dr. Thompson's presentation will be part of a session titled, "Clinical Studies and Therapeutic Development," which will be held on Thursday, November 5. The case study on QPI-1002 will detail Quark's progress in its independent development of the first systemic administration of a synthetic siRNA in humans, results from Quark's IND-enabling efficacy and toxicology studies and the largest cGMP manufacture of synthetic siRNA of its time. Dr. Feinstein's presentation, titled "Use of siRNA for Amelioration of Aseptic Lung Inflammatory Conditions," will take place on Wednesday, November 4 and will present Quark's preclinical studies for aseptic lung inflammation.

Daniel Zurr, Ph.D., President and Chief Executive Officer of Quark, said, "Drs. Thompson and Feinstein's presentations demonstrate Quark's leadership and continued innovation in the discovery and development of siRNA therapeutics. Quark's strength in preclinical discovery has promoted development of a robust pipeline that provides our company with growth opportunities within a broad range of therapeutic areas. We are nicely positioned to progress our clinical stage drug candidates, including t
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
2. Quark Pharmaceuticals Presents at Asia TIDES Conference
3. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014  This report analyzes the worldwide markets ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Rest of World. Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:9/16/2014)... Sept. 16, 2014  Denovo Biopharma, LLC, today ... oncology drug, from Eli Lilly and Company (NYSE: ... and commercialize enzastaurin globally, including transfer of all ... Lilly developed enzastaurin in a ... Phase 3 clinical trials for diffuse large B-cell ...
(Date:9/16/2014)... Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug ... billion in 2023 in the United States , ... Italy , Spain , the ... TNF-alpha inhibitors will remain the leading drug class in both sales ... constrained and patient shares will decline due to the uptake of ...
Breaking Medicine Technology:Global Digital Radiography Industry 2Global Digital Radiography Industry 3Global Digital Radiography Industry 4Global Digital Radiography Industry 5Global Digital Radiography Industry 6Global Digital Radiography Industry 7Global Digital Radiography Industry 8Global Digital Radiography Industry 9Global Digital Radiography Industry 10Global Digital Radiography Industry 11Global Digital Radiography Industry 12Global Digital Radiography Industry 13Global Digital Radiography Industry 14Global Digital Radiography Industry 15Global Digital Radiography Industry 16Global Digital Radiography Industry 17Global Digital Radiography Industry 18Global Digital Radiography Industry 19Global Digital Radiography Industry 20Global Digital Radiography Industry 21Global Digital Radiography Industry 22Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3
... (NYSE: CRY ), a leading tissue processing and ... today its results for the third quarter and first nine ... percent to a record $29.7 million compared to $28.4 million ... nine months increased 2 percent to a record $89.2 million ...
... Oct. 27, 2011 InterMune, Inc. (NASDAQ: ITMN ... 2011 financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. Eastern ... may participate in the conference call by dialing 888-567-5125 (U.S.) ...
Cached Medicine Technology:CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 2CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 3CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 4CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 5CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 6CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 7CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 8CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 9CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 10CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 11CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 12CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 13CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 14CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 15CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 16CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011 17InterMune to Release Third Quarter Financial Results on November 3 2
(Date:9/16/2014)... 17, 2014 Keep that sexy decolletage as ... the neck. , "The Face Whisperer Neck & Decollete ... Kathy Heshelow, founder of Sublime Beauty®. "It contains rich ingredients ... MSM and arnica." , A special ingredient is Argireline, known ... The rich anti-aging cream comes in an airless pump bottle, ...
(Date:9/16/2014)... Today, Zane Benefits, the #1 ... transitioning employees to individual health insurance. , ... Act (ACA) in full effect, many small and ... all of their employees towards individual health insurance. ... plans, coverage for pre-existing conditions, and premium tax ...
(Date:9/16/2014)... UWDress.com, the well-known wedding dress manufacturer and ... assortment online. Additionally, the firm has launched a ... big discounts now, up to 62 percent off. ... charming; it has won a lot of positive reviews ... is also providing big savings on many other items, ...
(Date:9/16/2014)... (September 16th, 2014; San Francisco) In a ... increasingly weighed against potential benefit, a Yale study ... or less-aggressive radiation procedures on elderly women with ... be presented at the 56th annual conference of ... Francisco. (Abstract 131: Evaluating National Practice in Radiotherapy ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous dress suppliers in ... gown collection. According to the company’s sales manager, all ... to 69% off) at present. Additionally, all the company’s old ... a frequent caller of your site. I like your products ... quite happy. All items are of good quality. I sincerely ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2
... between Uttar Pradesh Government Railway Police and Junior doctors ... Meerut by Meerut Nauchandi Express lead to injuring medicos ... the police personnel occupying the reserved seats of the ... seven state medical colleges for three days ordering enquiry ...
... appearing in the January 18 issue of The Journal of ... when adult neurons try to undergo division. This finding in ... development of the disease. ,"If you could ... from dying prematurely. This could be a fresh approach to ...
... are of the opinion that interstellar dust coming into our ... significance. The results have exceeded all expectations, according to Donald ... principal investigator, or lead scientist, for Stardust. ‘It's a huge ... ones, there are small ones’, he said. ...
... medicines will no longer be available to Canadians from supermarkets ... are aimed at preventing addicts from making crystal meth. //The ... be affected by the ban which will come into force ... sell about 15 medicines which are of the single ingredient ...
... masala and tobacco products near hospitals and educational institutions by the ... from beyond 500 meters from such institutions, according to the new ... that this is strictly adhered to. ,The youth ... product due its low price and easy availability. Children are also ...
... call to bedside phones cost higher than the call made ... charges levied on the bedside phones. // ... complaining of the bedside phone charges. ,The company ... the peak time costed around 49p per minute and at ...
Cached Medicine News:Health News:Dividing Nerve Cells Could Trigger Alzheimer's Disease 2Health News:Ofcom To Assess The Bedside Call Charges 2
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
Medicine Products: